We joined Ahmed Kaseb (M.D. Anderson Cancer Center) at ESMO 2019 to discuss recent findings from the randomised, open-label, perioperative phase 2 study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma (NCT03222076).
Questions
1. What are the major unmet needs in the treatment of resectable hepatocellular carcinoma (HCC)? (00:02)
2. What is the rationale for the combined use of nivolumab plus ipilimumab in this treatment setting? (02:19)
3. What factors are associated with clinical response to nivolumab plus ipilimumab? (03:03)
4. How do you expect these findings to impact the standard of care for resectable HCC? (04:16)
Ahmed Kaseb has received research funding from BMS.
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
